Show simple item record

dc.creatorDe Rossi, Nicola
dc.creatorScarpazza, Cristina
dc.creatorFilippini, Chiara
dc.creatorCordioli, Cinzia
dc.creatorRasia, Sarah
dc.creatorMancinelli, Chiara Rosa
dc.creatorRizzoni, Damiano
dc.creatorRomanelli, Giuseppe
dc.creatorCossi, Stefania
dc.creatorVettoretto, Nereo
dc.creatorBove, Sergio
dc.creatorManfredini, Silvano
dc.creatorBeindorf, Eva Andrea
dc.creatorMosca, Carlo
dc.creatorScipione, Vittorio
dc.creatorFlamminio, Gigliola
dc.creatorAlbini Albini, Elena
dc.creatorGiansiracusa, Paola
dc.creatorCapra, Ruggero
dc.creatoron behalf of Montichiari COVID-19 Study Group
dc.date.accessioned2020-09-21T13:39:05Z
dc.date.available2020-09-21T13:39:05Z
dc.date.created2020-08-01
dc.identifier.issn2589-5370spa
dc.identifier.otherhttps://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30203-0/fulltextspa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/13493
dc.format.extent9 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherEClinicalMedicinespa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjecttocilizumabspa
dc.subjecttocilizumabspa
dc.subjectanti-soluble IL-6 receptorspa
dc.titleEarly use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-upspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAcceso restringidospa
dc.identifier.doihttps://doi.org/10.1016/j.eclinm.2020.100459spa
dc.description.abstractenglishPneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage. An effective treatment aiming at reducing the inflammation without preventing virus clearance is thus urgently needed. Tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, has been proposed for treatment of patients with COVID-19.spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record